DL-AP3

Names

[ Name ]:
DL-AP3

[Synonym ]:
Alanine, 3-phosphono-
DL-2-Amino-3-phosphonopropionic acid
2-Amino-3-phosphonopropionic acid
D,L-2-Amino-3-phosphonopropionic Acid
(+-)-2-AMINO-3-PHOSPHONOPROPIONIC ACID ( AP-3)NMDA ANTAGONIST
2-amino-3-phosphopropanoic acid
3-Phosphonoalanine
UNII:0H89G8110O
3-Phosphono-DL-alanine
Aminophosphonopropionic acid
DL-2-Amino-4-phosphonopropionic acid
(±)-2-Amino-3-phosphonopropionic acid
2-amino-3-phosphonopropionate
2-amino-3-phosphonopropanoic acid
2-AP3

Biological Activity

[Description]:

DL-AP3 is a competitive mGluR1 and mGluR5 antagonist. DL-AP3 is also an inhibitor of phosphoserine phosphatase. DL-AP3 has neuroprotective effect[1][2][3].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> GPCR/G Protein >> mGluR

Research Areas >> Neurological Disease

[Target]

mGluR 1

mGluR 5

[In Vitro]

DL-AP3 (10 µM，6 小时) 减轻原代神经元中氧-葡萄糖剥夺 (OGD) 引起的损伤 (细胞活力)[1]。 DL-AP3 (10 µM，6 小时) 恢复原代神经元中 OGD 诱导的 p-Akt1 水平降低和细胞色素 C 增加[1]。 DL-AP3 (1-100 µM) 抑制大鼠脑磷酸丝氨酸磷酸酶的活性[2]。 DL-AP3 (10μM, 10min) 联合 SKF81297 (5μM) 在 Fmr1 KO 小鼠的切片中诱导显著的的长时程增强 (LTP)[3]。 Western Blot Analysis[1] Cell Line: Primary neurons Concentration: 10 µM Incubation Time: 6 h Result: Increased the decreased levels of p-Akt1, and decreased the increase of cytochrome C.

[In Vivo]

DL-AP3 (4 mg/kg, i.p., 持续 5 周) 联合 SKF81297 (1 mg/kg, i.p.) 减少 Fmr1 KO 小鼠多动表型[3]。 DL-AP3 (i.c.v.) 阻断绵羊内脏痛症状的发展，以及血浆中神经内分泌学变化[4]。 Animal Model: Fmr1 KO mice[3] Dosage: 4 mg/kg with SKF81297 (1 mg/kg) Administration: i.p., for 5 weeks. Result: Reduced the distance traveled by Fmr1 KO mice (open-field test). Reduced the swim latency on the final day in the Fmr1 KO mice (Morris Water Maze test).

[References]

[1]. Cui D, et al. DL-2-amino-3-phosphonopropionic acid protects primary neurons from oxygen-glucose deprivation induced injury. Bosn J Basic Med Sci. 2017 Feb 21;17(1):12-16.

[2]. Hawkinson JE, et al. The metabotropic glutamate receptor antagonist L-2-amino-3-phosphonopropionic acid inhibits phosphoserine phosphatase. Eur J Pharmacol. 1996 Jun 27;307(2):219-25.

[3]. Xu ZH, et al. Group I mGluR antagonist rescues the deficit of D1-induced LTP in a mouse model of fragile X syndrome. Mol Neurodegener. 2012 May 28;7:24.

[4]. B.F. Kania, et al. Supraspinal basis of analgesic and clinical effects of the metabotropic glutamate mGluR1 antagonist during colonic distension in sheep. Small Ruminant Research. 2014. 117 (1).